VANCOUVER, BC, July 21, 2022 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean (“ABO“) is supporting the Company’s growth with a CAD$‎‎9,000,000 ‎‎financing arrangement…


Previous articleIncannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A
Next articleEcstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy